BCL2 interacting protein 3 pseudogene 13Genealiases: []
Q-omics provides the consensus-scored BNIP3P13 profile across patient tissues and cancer cell-line models. BNIP3P13 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BNIP3P13 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, BNIP3P13 RNA expression shows 6,660 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, THCA, and STAD as cancer lineages where BNIP3P13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BNIP3P13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BNIP3P13 survival associations across molecular data types. BNIP3P13 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BNIP3P13 RNA expression–survival associations across cancer types. High BNIP3P13 expression shows unfavorable associations in KIRC, BRCA, LUAD, LGG, SKCM and STAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for BNIP3P13 RNA expression.
This table summarizes BNIP3P13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for BNIP3P13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BNIP3P13 shows lower tumor expression in THCA. The THCA box plot shows higher BNIP3P13 RNA expression in normal versus tumor tissue (log2 FC = −0.902, t-test p = .001).
This table shows molecular features associated with BNIP3P13 in patient tissues and cancer cell lines. In patient samples, BNIP3P13 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
